NephroQuiz: muscles and bananas.
Published in Healthcare & Nursing, Genetics & Genomics, and General & Internal Medicine
A 40-year-old African American man arrived at the emergency room experiencing profound muscle weakness. Past medical history revealed sporadic muscle tightness occurring 1-3 times per week, alleviated by consuming bananas. He was not using any medications, and his family history was noteworthy for hyperthyroidism and episodes of hypokalemia in his brother and mother.
Upon presentation, vital signs were temperature 98.4°F, blood pressure 127/83 mmHg, heart rate 111 beats/minute, respiratory rate 11 breaths/ minute, and oxygen saturation 96% on room air. Physical examination revealed pronounced weakness in both upper and lower extremities (strength assessed at 0/5) with areflexia.
Laboratory results are shown in Table 1. The electrocardiogram demonstrated sinus tachycardia with prolonged QTc interval of 606 ms. Swift replacement of hypokalemia effectively alleviated his symptoms, albeit leading to transient hyperkalemia that spontaneously resolved.
|
|
||
|
Tests |
Results |
Normal range |
|
Sodium |
139 mmol/L |
132-148 mmol/L |
|
Potassium |
<1.5 mmol/L |
3.5-5 mmol/L |
|
Chloride |
105 mmol/L |
98-111 mmol/L |
|
Bicarbonate |
21 mmol/L |
23-32 mmol/L |
|
Blood Urea Nitrogen |
18 mg/dL |
10-25 mg/dL |
|
Creatinine |
0.91 mg/dL |
0.7-1.4 mg/dL |
|
Calcium |
9.3 mg/dL |
8.4-10.5 mg/dL |
|
Albumin |
3.9 g/dL |
3.5-5.0 g/dL |
|
Total protein |
7.2 g/dL |
6.6-8.7 g/dL |
|
Glucose |
90 mg/dL |
65-100 mg/dL |
|
Magnesium |
1.9 mg/dL |
1.6-2.6 mg/dL |
|
Phosphorus |
2.1 mg/dL |
2.5-4.5 mg/dL |
|
AST |
64 U/L |
5-40 U/L |
|
ALT |
153 U/L |
5-41 |
|
Bilirubin- total |
0.3 mg/dL |
0.2-1.2 mg/dL |
|
Alkaline phosphatase |
79 U/L |
40-129 U/L |
|
Random urine K/Cr ratio |
10.7 mmol/g Cr |
17-121 mmol/g Cr |
|
TSH |
< 0.006 mcIU/mL |
0.270-4.200 mcIU/mL |
|
Free T3 |
13.0 pg/mL |
2.1-4.4 pg/mL |
|
Free T4 |
3.04 ng/dL |
0.9-1.70 ng/dL |
|
Thyroid Stimulating Ig (TSI) |
3.43 IU/L |
<=0.54 IU/L |
|
Thyroid Peroxidase Ab |
62.6 IU/mL |
0.0-9.0 IU/mL |
The correct answer, link to published case and explanation will be provided in the comment section.
Click here to read the original case report, published in BMC Nephrology. We encourage discussion of the case and questions in the comments.
Follow the Topic
-
BMC Nephrology
This is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
Your space to connect: The Primary immunodeficiency disorders Hub
A new Communities’ space to connect, collaborate, and explore research on Clinical Medicine, Immunology, and Diseases!
Continue reading announcementRelated Collections
With Collections, you can get published faster and increase your visibility.
Biomarkers in kidney disease diagnosis
BMC Nephrology is calling for submissions to our Collection on Biomarkers in kidney disease diagnosis.
Kidney disease remains a pressing global health issue, affecting millions and often leading to significant morbidity and mortality. The identification of reliable biomarkers has emerged as a promising avenue for enhancing the diagnosis and management of kidney diseases. Biomarkers can provide critical insights into the pathophysiology of renal conditions, facilitate early detection, and help tailor treatment strategies to individual patients. With the advent of advanced technologies in molecular biology and genomics, there is a growing interest in understanding how specific biomarkers can improve clinical outcomes in kidney disease.
The significance of advancing biomarker research in kidney disease diagnosis is underscored by recent breakthroughs in the identification of novel biomarkers that improve accuracy and timeliness in detection. These advancements are crucial for the early intervention and management of chronic kidney disease (CKD) and acute kidney injury (AKI). As research continues to evolve, integrating biomarkers into clinical practice can revolutionize the way kidney diseases are diagnosed, monitored, and treated. Furthermore, innovative biomarker applications may allow for better stratification of risk in populations at high risk for kidney disease, paving the way for proactive health management strategies.
Topics of interest for this Collection include, but are not limited to:
Novel biomarkers for kidney disease diagnosis
Early detection methods in kidney pathology
Clinical applications of renal biomarkers
Biomarkers and chronic kidney disease management
This Collection supports and amplifies research related to SDG 3 (Good Health and Well-being) and SDG 9 (Industry, Innovation, and Infrastructure).
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jan 30, 2026
Images in nephrology
BMC Nephrology is calling for submissions to our Collection on Images in nephrology.
This will be a unique collection where all submissions to the collection that meet consideration criteria will be included in an image competition. The Guest Editors for this collection will be the referees and will judge each image based on pre-defined criteria. We welcome submissions in the form of case reports, commentary articles and literature reviews to present their image. All images relating to the vast field of nephrology will be considered for publication and participation in the competition. The winner will receive a full APC waiver for their submission and for one future publication in BMC Nephrology. The second and third place winners will receive a full APC waiver for their submission to the collection. 1st and 2nd place winners will be invited to contribute to the BMC Nephrology blog. All winners will also be eligible for an invitation to BMC Editors Day – to visit a Springer Nature location and meet editorial staff.
Inspired by the multidisciplinary nature of our field, we want to welcome submissions that highlight the beauty of day-to-day nephrology. Intraoperative images, laboratory photographs, microscopy findings, anatomical models, hand-drawn art, radiology images and more will be considered. The image should be accompanied by a case report, commentary or review, describing the findings and importance of the image, the case or story behind it. Novelty will not be a criteria for consideration. Patient images are required to have appropriate patient consent for publication. Images accompanied by commentary and submitted as commentary articles will be considered on a case-by-case basis. Literature reviews will be considered pending editorial approval. In order to be published and considered in the competition, the articles must abide by scholarly publishing standards and journal guidelines.
The judges will evaluate the images based on, but not limited to, the following:
Image uniqueness
Adherence to BMC Nephrology scope
Quality and content of the image
Educational and public interest
Case and story behind the image
Submissions will be assessed for adherence to journal guidelines and publishing standards. Manuscripts that are rejected will be withdrawn from the competition automatically. If a manuscript is accepted, it will participate in the final evaluation by judges. All accepted manuscripts will be embargoed until the judging is completed. We will aim to carry out final judging quickly, as to not delay the publication of submitted works. The final day to submit a manuscript for consideration in the image contest will be November 1st, 2025. Final results will be tallied by November 30th, 2025 and the winners will be announced shortly after. The winners will be provided with an APC waiver immediately. All submitted manuscripts will undergo standard peer review and editorial evaluation as necessary.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Dec 31, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in
The correct answer is explained below:
.
.
.
.
.
The correct answer is: hypokalemic periodic paralysis.
Periodic paralysis (PP) is a rare channelopathy marked by recurrent episodes of flaccid skeletal muscle paralysis. Hypokalemic periodic paralysis (HypoPP) is categorized into familial or acquired forms. Triggers for episodes of HypoPP are primarily associated with intense exercise and high carbohydrate intake, and less frequently related to viral infections, stress, cold, salt consumption, and medications (such as glucocorticoids and insulin).
Familial HypoPP is associated with variants in the skeletal muscle sodium channel gene SCN4A in 20% of patients or the L-type calcium channel gene CACNA1S in 60% of patients. The majority of reported pathogenic variants involve arginine residues in S4 transmembrane segments, with notable hotspots at codons R528 and R1239. Generally, the existence of hyperthyroidism is more strongly associated with a diagnosis of acquired thyrotoxic periodic paralysis (TPP), with most cases occurring in Asian males without a family history of the condition. Pathogenic variants in KCNJ2 and KCNJ18 are associated with susceptibility to TPP. KCNJ2 and KCNJ18 encode Kir 2.1 and Kir2.6 respectively, inwardly rectifying potassium channels expressed in skeletal muscle and transcriptionally regulated by thyroid hormone.
Genetic testing in the discussed patient revealed a heterozygous pathogenic variant in CACNA1S [c.1583 G>A (p. R528H)] and normal sequencing of SCN4A, KCNJ2 and KCNJ18. The patient received a diagnosis of familial hypokalemic periodic paralysis and concurrent hyperthyroidism due to Graves’ disease. The likelihood of TPP in this case is reduced, given the patient is not of Asian descent, has a family history of HypoPP, and lacks identifiable variants in KCNJ2 and KCNJ18. The pathogenic variant observed in this case has been documented previously. This variant leads to a substantial reduction in the whole-cell calcium channel current and induces depolarization of the resting cell potential in response to hypokalemia.
Management of acute paralytic episodes involves maintaining proper control of serum potassium levels, necessitating vigilant monitoring for post-treatment hyperkalemia. Lifestyle and dietary modifications to avoid triggering factors are integral to treatment. Although the precise mechanism is not fully elucidated, carbonic anhydrase inhibitors have demonstrated efficacy in reducing the frequency of familiar HypoPP episodes. There is variability in the response to carbonic anhydrase inhibitors based on genotype; individuals with CACNA1S variants tend to exhibit a more favorable response compared to SCN4A variants. Additionally, the incorporation of a potassium-sparing diuretic, either in conjunction with carbonic anhydrase inhibitors or as a standalone treatment, may offer advantages for specific patients.
Read more in the published article: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03749-x
Read more in the published article: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03749-x